AAP
DMAC icon

Arax Advisory Partners’s DiaMedica Therapeutics DMAC Stock Holding History

Arax Advisory Partners’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32
Closed -$219 – 4197
2025
Q3 		$219 Buy
+32
New +$174 ﹤0.01% 3442

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Arax Advisory Partners's DMAC Position: Q4 2025 in Review

Arax Advisory Partners sold out of DiaMedica Therapeutics (DMAC) in Q4 2025, closing a stake of 32 shares — an estimated $219 sold.

Arax Advisory Partners first reported a position in DMAC in Q3 2025 and held it in 1 quarter. The position peaked at $219 in Q3 2025. 92 funds tracked by Wall St. Rank hold DMAC as of Q4 2025.

  • Arax Advisory Partners reported no remaining DiaMedica Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 32 DiaMedica Therapeutics shares in Q4 2025, an estimated $219.
  • Arax Advisory Partners first reported a position in DiaMedica Therapeutics in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's DiaMedica Therapeutics position peaked at $219 in Q3 2025.
  • 92 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.